Rabbit anti-thymocyte globulin: Evidence for clinical benefit in high immunological risk kidney transplantation

Martin L. Mai, Hani Wadei, Thomas A. Gonwa

Research output: Contribution to journalReview article

Abstract

Rabbit anti-thymocyte globulin is used worldwide to treat and prevent rejection in kidney transplantation. Multiple mechanisms of action of this polyclonal preparation are responsible for its success. Studies have supported clinical benefits of rabbit anti-thymocyte globulin in high immunological risk kidney transplant recipients when used as an induction agent at the time of transplant and for treatment of rejection when compared to other antibody therapy. The evidence of this clinical benefit will be reviewed in addition to examining the dosing and safety profile of rabbit anti-thymocyte globulin.

Original languageEnglish (US)
Pages (from-to)39-49
Number of pages11
JournalClinical Medicine Insights: Therapeutics
Volume3
DOIs
StatePublished - Jan 1 2011

Keywords

  • High immunological risk
  • Kidney transplantation
  • Rabbit anti-thymocyte globulin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Rabbit anti-thymocyte globulin: Evidence for clinical benefit in high immunological risk kidney transplantation'. Together they form a unique fingerprint.

  • Cite this